Kornimate/medical-research-clean huggingface dataset:
metabolism of lipids in advanced cancer

Conditions: Lung Neoplasms; Cachexia

Summary: the causes of failing nutrition status in advanced cancer are not well known. the way fat is moved, stored, burned or changed into other compounds may be affected and will be followed in patients using a tracer and other blood tests. the investigators hypothesize that fat loss and wasting results from low essential fatty acid availability in the body. changes may occur in the liver that limits distribution and availability of fat to the body as an energy source or for other essential functions.

weight loss in cancer is the result of breakdown of fat (lipid) and muscle protein reserves. this research will explore how people with cancer use fat in their body through the use of tracers and measures in the blood. a stable isotope of hydrogen called 'deuterium' is used to trace the production of different fats by the liver. other methods will determine how much and what types of fat are transported around the body. body composition will be determined by ct scan and related to fat measures.

Eligibility criteria:
inclusion criteria: * low plasma phospholipids or low plasma ratio of triglycerides to free fatty acids * recent weight loss * advanced stage lung cancer (stage 3 or 4) exclusion criteria: * having symptoms that may affect measures of fat metabolism (nausea, vomiting, problems swallowing, etc.) * taking n-3 fatty acid supplements such as fish oil

Keywords: lipogenesis lipolysis phospholipids body composition nutritional status lipid metabolism
mesenchymal stem cell secretome in severe cases of covid-19

Conditions: COVID-19

Summary: this study is a multi-centre randomized controlled trial involving severe covid-19 patients. the intervention group will receive mesenchymal stem cell secretomes and standard covid-19 therapy, while the control group receive placebo and standard covid-19 therapy. clinical presentation, inflamatory marker, laboratory and radiological parameters, rt-pcr conversion, safety profile, and mortality rate will be monitored for a maximum of 14 days after intervention.


Eligibility criteria:
inclusion criteria: 1. all individuals aged 18 to 65 years 2. it has been confirmed positive for covid-19 by throat swab / sputum / brochoalveolar lavage (bal) with real-time reverse transcription polymerase chain reaction (rt-pcr) 3. categorized as a severe case of covid-19 patient 4. agree to participate and sign the informed consent exclusion criteria: 1. history of allergy to penicillin, streptomycin, and amphotericin-b 2. have any cancer conditions 3. active in other intervention studies 4. have had other intervention studies in the last 3 months

Keywords: severe covid-19 secretome mesenchymal stem cell cytokine
extracorporeal cytokine adsorption as additive treatment of car-t associated cytokine release syndrome (crs)

Conditions: Cytokine Release Syndrome; CAR-T

Summary: patients with severe car-t cell associated cytokine release syndrome (crs) (defined as vasopressor dependent) will be treated with standard of care (soc) + cytokine adsorption (6hourly for 24 hrs). primary endpoint is the change in plasma il-6 between 0 and 24 hrs.


Eligibility criteria:
inclusion criteria: * severe crs (\> 3) and / or severe cres (\>3) and - crs/cres onset \< 6 hrs exclusion criteria: * heparine allergy * contraindication for anticoagulation
efficacy and safety of lumiracoxib in patients with primary knee osteoarthritis (oa)

Conditions: Osteoarthritis

Summary: this 39-week, active controlled, study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (oa) of the knee who participated in the 13-week core ccox189a2361 study.


Eligibility criteria:
inclusion criteria: * any patient who completed the core study 2361 may enter the extension trial upon signing informed consent. a patient is defined as completing if he/she completed the core study 2361 up to and including visit 6 (week 13) without a major protocol violation. exclusion criteria: * those patients for whom continued treatment in the extension study is not considered appropriate by the treating physician * those patients who were non-compliant or who demonstrated a major protocol violation in the core study. other protocol-defined inclusion/exclusion criteria may apply

Keywords: osteoarthritis lumiracoxib celecoxib cox-2 knee
quality of pediatric resuscitation in a multicenter collaborative

Conditions: Cardiac Arrest; Cardiopulmonary Arrest

Summary: this is a prospective, observational, multi-center cohort study of pediatric cardiac arrests. the purpose of the study is to determine the association between chest compression mechanics (rate, depth, flow fraction, compression release) and patient outcomes. in addition, the investigators will determine the association of post cardiac arrest care with patient outcomes.

cardiac arrests in children are a major public health problem. thousands of children each year in the usa are treated with cardiopulmonary resuscitation (cpr) and managed after their cardiac arrest. neurological outcomes following these in-hospital cpr events are often abnormal. as children with neurological deficits following cpr are a major burden for families and society, improving neurological outcomes through superior chest compression delivery during cpr and optimal care and management after cardiac arrest is an important clinical goal. therefore, the objective of this investigation is to obtain evidentiary support to associate the relationship of quantitative cpr quality data (depth, rate, chest compressions (cc) fraction, compression release) during cpr, post-cardiac arrest care (pcac) and patient survival in those children who suffer an arrest within the study (res-q) network.

Eligibility criteria:
inclusion criteria: * patient received chest compressions for at least 1 minute * patient between gestational age ≥37 weeks and 17 years of age * patient had a quality of cpr measurements device (eg., zoll medical chest compression sensor) in place during chest compressions exclusion criteria: * patient on extracorporeal membrane oxygenation (ecmo) therapy at beginning of cpr event

Keywords: chest compressions cardiopulmonary resuscitation
vitamin d plus fluticasone propionate

Conditions: Seasonal Allergic Rhinitis

Summary: the objectives of this study would be to see if the addition of vitamin d to fluticasone propionate provides greater symptomatic relief in patients with seasonal allergic rhinitis compared to fluticasone propionate treatment alone.


Eligibility criteria:
inclusion criteria 1. males and females between 18 and 45 years of age. 2. history of tree, grass and/or ragweed allergic rhinitis. 3. positive skin test to tree, grass and/or ragweed antigen. 4. positive response to screening nasal challenge. exclusion criteria 1. physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease. 2. pregnant or lactating women. 3. upper respiratory infection within 14 days of study start.
goodmoms: a multimodel pregnancy and postpartum intervention for gestational diabetics

Conditions: Gestational Diabetes Mellitus; Pregnancy

Summary: this study includes a behavioral educational intervention that focuses on healthy eating and physical activity during pregnancy and the postpartum among women newly diagnosed with gestational diabetes mellitus (gdm).

this is a pilot trial in which 30 women newly diagnosed with gestational diabetes are randomized to either one of two groups: 1) active internet intervention or 2) self-directed educational intervention. the primary pregnancy outcome is change in a1c. the primary postpartum outcome is weight.

Eligibility criteria:
inclusion criteria: * diagnosed with gestational diabetes * planning to delivery with the study area exclusion criteria: * pre-existing diabetes (type 1 or type 2 diabetes) * non-english speaking * not planning to delivery in the study area

Keywords: gestational diabetes
virtual reality's role in see&treat hysteroscopy

Conditions: Endometrial Cancer; Endometrial Diseases; Myoma;Uterus; Endometrial Hyperplasia

Summary: the aim of the study is to evaluate the feasibility and effectiveness of virtual reality technology in outpatient hysteroscopy to improve pain and anxiety management and spread the diffusion of see \& treat philosophy.


Eligibility criteria:
inclusion criteria: exclusion criteria: -

Keywords: outpatient hysteroscopy virtual reality technology pain and anxiety management see & treat
effect of different music types on implant surgery anxiety

Conditions: Anxiety, Dental

Summary: a general term, dental anxiety, is defined as fear or an abnormal concern to visit the dentist for unwanted concerns about preventive care and dental procedures. anxiety; dental examinations or treatment can be prevented or postponed. this delay in dentistry typically leads to much more serious dental problems, often leading to more expensive, more invasive and possibly emergency treatment. therefore, reducing anxiety is important both in terms of patient, physician and cost.


Eligibility criteria:
inclusion criteria: * will undergo elective implant surgery, * between 40-70 years exclusion criteria: * who does not agree to participate in the study, * under 40, over 70 years, * patients with ear disorders (ie, not suitable for musical intervention), * arrhythmia * patients with physical condition iii or higher (american society of anesthesiologists)
a prospective study of conventional bone marrow biopsy versus portomar(tm) biopsy

Conditions: Hematologic Malignancy

Summary: this is a self-controlled, prospective trial. the objective of this trial is to evaluate the efficacy and safety of the portomar(tm) device for bone marrow biopsy.

this is a self-controlled, prospective trial. subjects will undergo conventional bone marrow biopsy compared to bone marrow biopsy with the portomar(tm) device. subjects will be evaluated at multiple time points comparing the two biopsies. data through the 6 month time point will be used for regulatory submission to the fda. additionally subjects will be followed for two years post enrollment.

Eligibility criteria:
inclusion criteria: * • patients with a previous bone marrow disorder diagnosis who will require multiple bone marrow biopsies over the course of their treatment, for example patients with plasma cell dyscrasia or leukemia. * men and non-pregnant women of age ≥ 21 years with ecog performance status ≤ 2. * any hematologic (platelets above 50, anc \> 1.0, hemoglobin \> 7), renal (patients not on dialysis), or hepatic (patients with bilirubin below 2.5) function status suitable to undergo port implantation and subsequent bone marrow biopsies. * patients must be able to understand and be willing to sign a voluntary informed consent form and agree to compliance with the protocol schedule; with the knowledge that they may withdraw consent at any time without impact on future medical care. exclusion criteria: * • patients with any other ongoing, concomitant, comorbid illness including but not limited to uncontrolled diabetes, nyha class iii or worse heart failure, uncontrolled coronary artery disease/arrhythmia. * patients unable to comply with the study schema. * confirmed pregnancy at time of screening or on implantation day prior to anesthesia/sedation. * patients unable to come off of anticoagulation medications for their procedure. * patients with active infection. * patients with \ 2.5 cm of soft tissue between screw head and skin at the target site of implantation. this is based on the patient's prior imaging studies (i.e. ct/mr or ultrasound imaging). * patient has contra-indication to conscious sedation or anesthesia services * patients who have had prior bone marrow biopsy within 2 weeks of the study biopsy. * patients with coagulopathy such that inr cannot be corrected \< 2.0. * patients who are prisoners or wards of the court. * patients with alcohol or substance abuse disorder defined by dsm v criteria. * patients with the diagnosis of a major psychiatric disorder such as schizophrenia or major depression defined by the dsm-v criteria. * patients with osteoporosis defined as l1 vertebrae bone density lower than 90 hounsfield units
performance of non-injected mr enterography compared to a conventional mr enterography protocol with contrast agent injection

Conditions: Crohn Disease

Summary: entero-mri is indicated in crohn's disease as part of the initial work-up or follow-up (to assess response to treatment, complications). the protocol for carrying out the examination complies with precise specifications set out in international recommendations. to perform the test, the small intestine must be distended with a hyperosmolar product. this protocol is applied to all patients, with no distinction or adaptation. the total duration of the examination is sometimes difficult for patients to bear. ingestion of the product to obtain distension of the small intestine is often poorly tolerated by patients. in a number of cases, the entero-mri may have been normal due to symptomatology regression or other diagnosis. the patient therefore underwent a complete examination similar to that of a patient with a pathology requiring characterization. in this context, the investigators hypothesize that fast mr sequences are sufficient to discriminate between normal and abnormal examinations.


Eligibility criteria:
inclusion criteria: patient with mr enterography examination for follow-up or suspected crohn's disease no exclusion criteria.
mirabegron combined with behavioral intervention for overactive bladder：a prospective multicenter randomized controlled clinical study

Conditions: Overactive Bladder

Summary: the purpose of this study was to assess the efficacy, safety and tolerability of mirabegron and behavioral combination versus mirabegron alone in the treatment of women with overactive bladder (oab）.


Eligibility criteria:
inclusion criteria: * 1. female aged between 40-60 years old, and no abnormalities were found in general examination, neurological examination and pelvic examination. 2. patients with urgent urination for more than 3 months, with or without urgent incontinence, often with frequent micturition and nocturia, have normal urine routine. 3. the patients who were diagnosed as oab by the following questionnaires, with 6≤ score ≤11 is moderate oab, with score≥12 is severe oab, and selected moderate and severe oab patients. 4. willing to join the study with signed icf. exclusion criteria: * 1. other diseases as obvious reasons causing oab symptoms. 2. patients with hypertension, of whom blood pressure is as high as 180/110 mm hg or above. 3. patients with gynecological malignancies, pelvic radiation therapy, stress urinary incontinence or mixed urinary incontinence with predominant stress incontinence. 4. those taking oab treatment drugs; 5. pregnant (blood g-hcg determination if necessary) or lactating women; 6. women with liver and kidney dysfunction, immunosuppressive agents, blood diseases, diabetes, mental illness or other serious diseases. 7. poor compliance. 8. allergic constitution, or allergic to the type of study drug
tirofiban intracoronary bolus-only versus intravenous bolus plus infusion in stemi patients

Conditions: Acute Myocardial Infarction

Summary: the aim of this randomized trial is to compare the efficacy of high dose tirofiban administered as either an intracoronary bolus alone or as an intravenous bolus followed by a maintenance infusion with respect to microvascular perfusion and long term left ventricular infarct size, volumes and function.

primary percutaneous coronary intervention (pci) is currently the treatment of choice for patients with acute st elevation myocardial infarction (stemi). nevertheless, despite restoration of normal epicardial flow, myocardial perfusion remains impaired in approximately half of patients and is associated with a poor prognosis. a variety of invasive and non-invasive techniques have been proposed to evaluate microvascular perfusion and several invasive hemodynamic measures have been closely associated with microvascular damage.in order to improve microvascular perfusion after primary pci, a variety of treatment strategies have been developed, such as adjunctive administration of glycoprotein iib/iiia inhibitors (gpis). although current acc/aha guidelines recommend that small molecule gpis should be administered as a bolus followed by 18 hours of continuous infusion, changes in clinical practice may obviate the need for a maintenance infusion in current practice. we hypothesized that when tirofiban is administered via intracoronary route, a bolus-only strategy may even be superior to intravenous bolus plus infusion strategy in maintaining myocardial perfusion. in order to evaluate microvascular function, we used a guidewire tipped with pressure and temperature sensors and measured the coronary hemodynamic parameters, as the index of microvascular resistance and coronary flow reserve, measures which have been closely associated with microvascular damage. in order to increase the predictive value of these indices, we performed these measurements four to five days after mi, because it has been shown that the extent of microvascular dysfunction changes, particularly within first 48 hours after reperfusion and stabilizes between 2 days and 1 week after perfusion

Eligibility criteria:
inclusion criteria: * typical ongoing ischemic chest pain for longer than 30 minutes * st segment elevation of 0,1 mv or greater in at least two contiguous leads or a new left bundle branch block on the initial ecg. exclusion criteria: * cardiogenic shock and / or clinical instability * previous stemi * malignant life threatening diseases * presence of an additional lesion causing more than 50% narrowing distal to the culprit lesion * contraindications to aspirin, clopidogrel, or heparin * inability to give informed consent.

Keywords: primary angioplasty tirofiban microcirculation
cinacalcet in management of secondary hyperparathyroidism in haemodialysis patients

Conditions: Secondary Hyperparathyroidism

Summary: this is a single arm, open-labelled study to determine the effectiveness of combination cinacalcet with vitamin d analogue in the treatment of severe hyperparathyroidism in patients with esrf on haemodialysis. patients will be started on po cinacalcet 25mg od + po/iv active vitamin d analogues adjusted by increments/decrements in steps of 1 mcg 3x per week every 1-4 weeks until the corrected calcium level is within 2.4-2.54 mmol/l. after ipth has reached 2-9x uln, patient enters maintenance phase. if serum calcium falls below 2.1mmol/l, active vit d dose will be increased and if it is above 2.54 mmol/l, the dose will be decreased. percentage reduction of ipth levels from baseline at 6,12 and 24 months treatment and percentage of patients achieving ipth levels within the target range of 2-9x upper limit normal at 6, 12 and 24 months will be determined

many patients on haemodialysis will develop secondary hyperparathyroidism. vitamin d analogues such as alphacalcidol are needed to bring their ipth levels down to normal. however, these analogues can cause hypercalcaemia, thus its doses are limited by this effect. cinacalcet, which is currently not widely available to patients in hospitals, is a calcimimetic that can reduce both ipth and serum calcium levels. no studies have yet to be carried out investigating the outcome of using low doses of cinacalcet as a means of optimizing doses of vitamin d analogues by keeping calcium levels from going over the upper limit. so a single arm, open-labelled study has been designed to determine the effectiveness of combination cinacalcet with vitamin d analogue in the treatment of severe hyperparathyroidism in patients with esrf on haemodialysis. no formal sample size calculation was done as this is a proof of concept study. power calculation will be done at the end based on the primary outcome of the study. methodology: patients will be started on po cinacalcet 25mg od + po/iv active vitamin d analogues adjusted by increments/decrements in steps of 1 mcg 3x per week every 1-4 weeks until the corrected calcium level is within 2.4-2.54 mmol/l. after ipth has reached 2-9x uln, patient enters maintenance phase. if serum calcium falls below 2.1mmol/l, active vit d dose will be increased and if it is above 2.54 mmol/l, the dose will be decreased. percentage reduction of ipth levels from baseline at 6,12 and 24 months treatment and percentage of patients achieving ipth levels within the target range of 2-9x upper limit normal at 6, 12 and 24 months will be determined.

Eligibility criteria:
inclusion criteria:1. end stage renal failure (esrf) patients on haemodialysis with ipth levels more than 9x upper limit normal 2. patients who has history of active vitamin d analogue doses limited by hypercalcaemia (\>2.54 mmol/l) exclusion criteria: 1. pregnant or breastfeeding or planning to become pregnant 2. life expectancy of 6 months or less 3. history of decompensated liver disease
predictors of heart failure after st-segment elevation myocardial infarction (hf-express)

Conditions: Heart Failure and ST Elevation Myocardial Infarction

Summary: objective: the purpose of this project is to study the post miyocardial infaction (mi) damage and subsequently developed post-infarct cardiac repair process on the basis of cellular, molecular and imaging techniques. besides this, whole genomesequencing and analysis (gwas) will be performed to determine common varying genetic loci in order to anticipate whetherthese findings and its related pathways would be the predictors of adverse remodeling after mi or not.

a brief description of the issue and the original value of the subject: epidemiological studies show a clear increase ininfarct-related complications due to increased survival after mi and aging population. heart failure is the most prevalent complication after mi, which has reached epidemic proportions in western societies. for the period between 2010 and 2030,according to projections made in developed countries, about 10% increment in all cardiovascular disease is being predictedhowever increment in heart failure (hf) would be such a dramatic figure which is about 25%. hf is an increasing burden tosociety and healthcare systems, since its prevalence and incidence is dramatically increasing. there has not been aprospective study that assesses the exact cellular and geometric course after mi in human. this study will allow us tounderstand the behavior of cells involved in cardiac repair after mi. in addition, it will show us the exact functional andgeometric course after mi. finally, the current study will also provide novel diagnostic and therapeutic targets via genomic andproteomic studies. all together, we envision to find new efficient ways to identify/treat patients at risk to develop hf after mi.

Eligibility criteria:
inclusion criteria: 18-80 years old patients with myocardial infarction in the first 12 hours timi 3 flow following pci exclusion criteria: right ventiricular myocardial infarction cardiogenic shock history of cabg, pci or valvular disease history of cardiomyopathy severe lv hypertrophy no reflow after pci chronic kidney disease (gfr\<60) systemic inflammatory disease

Keywords: stemi, heart failure, inflammation, haptoglobin polymorphisms, adverse remodeling, genetics, gwas, mri
assessment of the effectiveness of menopur in intrauterine insemination

Conditions: Infertility

Summary: the purpose of this study is to assess the effectiveness of menopur to achieve clinical pregnancy in females undergoing intrauterine insemination in clinical practice.


Eligibility criteria:
inclusion criteria: * infertile couples for over one year (primary or secondary) or infertile women (or not) with indication of pai or dai * seminal sample suitable for artificial insemination treatment according to the criterion of each centre * patient prescribed therapy with menopur in artificial insemination exclusion criteria: * contraindications to intrauterine insemination * contraindications to menopur